Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin vs Campath-1H vs Daclizumab in Renal Transplantation
NCT00685061Phase 4Completed
- Sponsor
- University of Miami
- Start
- Nov 2002
- Primary completion
- Sep 2004
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of antithymocyte globulin and alemtuzumab in kidney transplant rejection (3 arms), sponsored by University of Miami. Primary endpoint: Incidence and severity of biopsy-proven acute rejection at 1 year. Started Nov 2002; status: completed.
02
Drugs
antithymocyte globulinalemtuzumab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00685061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00685061.